A pan-cancer organoid platform for precision medicine - PubMed (original) (raw)
. 2021 Jul 27;36(4):109429.
doi: 10.1016/j.celrep.2021.109429.
Madhavi Kannan 1, Lee F Langer 1, Benjamin D Leibowitz 1, Aicha Bentaieb 1, Andrea Cancino 1, Igor Dolgalev 2, Bridgette E Drummond 1, Jonathan R Dry 1, Chi-Sing Ho 1, Gaurav Khullar 1, Benjamin A Krantz 2, Brandon Mapes 1, Kelly E McKinnon 1, Jessica Metti 1, Jason F Perera 1, Tim A Rand 1, Veronica Sanchez-Freire 1, Jenna M Shaxted 1, Michelle M Stein 1, Michael A Streit 1, Yi-Hung Carol Tan 3, Yilin Zhang 1, Ende Zhao 3, Jagadish Venkataraman 1, Martin C Stumpe 1, Jeffrey A Borgia 4, Ashiq Masood 5, Daniel V T Catenacci 2, Jeremy V Mathews 6, Demirkan B Gursel 6, Jian-Jun Wei 6, Theodore H Welling 2, Diane M Simeone 2, Kevin P White 1, Aly A Khan 7, Catherine Igartua 8, Ameen A Salahudeen 9
Affiliations
- PMID: 34320344
- DOI: 10.1016/j.celrep.2021.109429
Free article
A pan-cancer organoid platform for precision medicine
Brian M Larsen et al. Cell Rep. 2021.
Free article
Abstract
Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of scalable and reproducible methods to develop and profile these models. We describe a robust pan-cancer TO platform with chemically defined media optimized on cultures acquired from over 1,000 patients. Crucially, we demonstrate tumor genetic and transcriptomic concordance utilizing this approach and further optimize defined minimal media for organoid initiation and propagation. Additionally, we demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers. The pan-cancer platform, molecular data, and neural-network-based drug assay serve as resources to accelerate the broad implementation of organoid models in precision medicine research and personalized therapeutic profiling programs.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.A.K., A.A.S, A.B., B.D.L., B.M., B.M.L, C.-S.H., C.I., G.K., J.F.P., J.V.M., J.R.D., K.E.M., K.P.W., L.F.L, M.K., M.M.S., T.A.R, V.S.-F., J.V., and Y.Z are employees and shareholders of Tempus Labs. A.C., B.E.D., J.M.S., and M.A.S. are employees of Tempus Labs. A.A.K., A.A.S, B.M., B.M.L., M.K., M.M.S., V.S.-F., J.V., and Y.Z. are inventors on patents related to organoid technology. K.P.W. is a Senior Group Leader at A(∗)STAR. A.A.S. holds a faculty position at the University of Illinois at Chicago.
Similar articles
- Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D, Tan Y, Li Z, Li W, Yu L, Chen W, Liu Y, Liu L, Guo L, Huang W, Zhao Y. Chen D, et al. J Clin Endocrinol Metab. 2021 Apr 23;106(5):1410-1426. doi: 10.1210/clinem/dgab020. J Clin Endocrinol Metab. 2021. PMID: 33524147 - Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
Qu S, Xu R, Yi G, Li Z, Zhang H, Qi S, Huang G. Qu S, et al. Mol Biomed. 2024 Feb 12;5(1):6. doi: 10.1186/s43556-023-00165-9. Mol Biomed. 2024. PMID: 38342791 Free PMC article. Review. - Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Praharaj PP, et al. Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):117-127. doi: 10.1016/j.bbcan.2017.12.005. Epub 2018 Jan 31. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29360544 Free PMC article. Review. - Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
Votanopoulos KI, Mazzocchi A, Sivakumar H, Forsythe S, Aleman J, Levine EA, Skardal A. Votanopoulos KI, et al. Ann Surg Oncol. 2019 Jan;26(1):139-147. doi: 10.1245/s10434-018-7008-2. Epub 2018 Nov 9. Ann Surg Oncol. 2019. PMID: 30414038 Free PMC article. - An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H. Kopper O, et al. Nat Med. 2019 May;25(5):838-849. doi: 10.1038/s41591-019-0422-6. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011202
Cited by
- The drug-induced phenotypic landscape of colorectal cancer organoids.
Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, Herweck F, Srour-Mhanna K, Miersch T, Valentini E, Boonekamp KE, Hauber V, Gutting T, Frank L, Belle S, Gaiser T, Buchholz I, Jesenofsky R, Härtel N, Zhan T, Fischer B, Breitkopf-Heinlein K, Burgermeister E, Ebert MP, Boutros M. Betge J, et al. Nat Commun. 2022 Jun 6;13(1):3135. doi: 10.1038/s41467-022-30722-9. Nat Commun. 2022. PMID: 35668108 Free PMC article. - Label-free characterization of organoids with quantitative confocal Raman spectral imaging.
Coughlan MF, Perelman LT. Coughlan MF, et al. Cell Rep Methods. 2023 Apr 13;3(4):100457. doi: 10.1016/j.crmeth.2023.100457. eCollection 2023 Apr 24. Cell Rep Methods. 2023. PMID: 37159664 Free PMC article. - [A review on depth perception techniques in organoid images].
Sun Y, Huang F, Zhang H, Jiang H, Luo G. Sun Y, et al. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024 Oct 25;41(5):1053-1061. doi: 10.7507/1001-5515.202404036. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2024. PMID: 39462675 Free PMC article. Review. Chinese. - OrganoID: A versatile deep learning platform for tracking and analysis of single-organoid dynamics.
Matthews JM, Schuster B, Kashaf SS, Liu P, Ben-Yishay R, Ishay-Ronen D, Izumchenko E, Shen L, Weber CR, Bielski M, Kupfer SS, Bilgic M, Rzhetsky A, Tay S. Matthews JM, et al. PLoS Comput Biol. 2022 Nov 9;18(11):e1010584. doi: 10.1371/journal.pcbi.1010584. eCollection 2022 Nov. PLoS Comput Biol. 2022. PMID: 36350878 Free PMC article. - Using Organotypic Tissue Slices to Investigate the Microenvironment of Pancreatic Cancer: Pharmacotyping and Beyond.
Weitz JR, Tiriac H, Hurtado de Mendoza T, Wascher A, Lowy AM. Weitz JR, et al. Cancers (Basel). 2021 Oct 5;13(19):4991. doi: 10.3390/cancers13194991. Cancers (Basel). 2021. PMID: 34638476 Free PMC article. Review.